对质母细胞瘤分子向疗法和免疫疗法的III期临床试验的进展
Yuekun Wang1, Shenglan Li2, Yichen Peng2
1Department of Neurosurgery, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Cancer innovation
|December 13, 2023
概括
质母细胞瘤治疗面临挑战,因为标准护理提供了不良的预后. 向药物和免疫疗法显示出希望,但需要进一步的研究,以改善质瘤患者的生存率.
科学领域:
- 神经瘤学神经瘤学
- 癌症治疗方法 癌症治疗方法
- 免疫学 免疫学 免疫学
背景情况:
- 质母细胞瘤 (GBM) 是最常见的中枢神经系统原发性瘤,预后不佳.
- 目前的标准护理,包括手术,temozolomide和瘤治疗领域,提供有限的长期生存益处.
- 针对性治疗和免疫治疗的出现为GBM管理提供了新的途径.
研究的目的:
- 对质瘤的向药物和免疫疗法的现有研究进行全面审查.
- 讨论这些新治疗方法在质瘤治疗中的挑战和未来前景.
主要方法:
- 对GBM中向药物的III期临床试验的系统审查.
- 对III期临床试验的审查,涉及质瘤的各种免疫疗法,包括检查点抑制剂,疫苗和病毒疗法.
主要成果:
- 向药物在GBM中表现出有限的疗效,只有少数患者的生存时间延长.
- 免疫疗法,如免疫检查点抑制剂和疫苗,已在多个III期试验中进行了研究.
- 尽管有进展,但很大一部分患者没有从当前的向和免疫治疗策略中受益.
结论:
- 向药物和免疫疗法提供了新的希望,但面临的挑战在实现广泛有效的质瘤.
- 进一步的研究对于克服治疗耐药性和优化患者选择这些先进疗法至关重要.
- 澄清向药物和免疫疗法开发的未来方向对于改善质瘤患者的治疗结果至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529